Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.73 |
| ▸ | NPC1 | O15118 | 2/20 | 0.70 |
| ▸ | RAB9A | P51151 | 2/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21533499 | 0.84 | LMNA (1.00) | LMNANPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL21533494 | 0.84 | LMNA (0.73) | LMNANPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL21533442 | 0.81 | LMNA (0.68) | LMNANPC1RAB9AALDH1A1KMT2A | |
| SCHEMBL1849856 | 0.80 | SMN1; SMN2 (0.73) | NPC1RAB9ASMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL1848388 | 0.79 | L3MBTL1 (0.72) | NPC1RAB9ASMN1; SMN2KMT2AHTT | |
| SCHEMBL28154099 | 0.79 | TSHR (0.68) | LMNANPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL21533443 | 0.78 | ALDH1A1 (0.88) | LMNANPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL1852828 | 0.77 | RAB9A (0.64) | NPC1RAB9ASMN1; SMN2KMT2ATP53 | |
| SCHEMBL5788823 | 0.76 | RAB9A (0.58) | NPC1RAB9ASMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL22607250 | 0.76 | KMT2A (0.84) | LMNANPC1RAB9ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190330167-A1 | ACTIVATORS OF HIV LATENCY | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2019-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190330167-A1 | ACTIVATORS OF HIV LATENCY | NFATC1, EP300, CD69 | LMNA 1695/4885NPC1 652/4885RAB9A 2862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.